Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
07:33pm, Thursday, 04'th Aug 2022
Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis Shares Slide On CEO Transition
05:07pm, Monday, 18'th Jul 2022
Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022. After ten years of leading the transformation a
Why Codexis Shares Are Slumping Today
06:55am, Friday, 15'th Jul 2022
Codexis Inc (NASDAQ: CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the propr expectation of $152 million - $158 million. FY22 product rev
Codexis stock drops as forecast comes in below Street estimate
05:19pm, Thursday, 14'th Jul 2022
Codexis Inc. CDXS shares fell in the extended session Thursday after the biotech company lowered its revenue forecast for the year and said that sales from Pfizer Inc. PFE would come in at the low end
Codexis, Inc. (CDXS) CEO John Nicols on Q1 2022 Results - Earnings Call Transcript
07:44pm, Thursday, 05'th May 2022
Codexis, Inc. (NASDAQ:CDXS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President an
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
04:35pm, Monday, 02'nd May 2022
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presenta
After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)
10:49am, Wednesday, 27'th Apr 2022
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
Codexis to Report First Quarter 2022 Financial Results on May 5
04:05pm, Thursday, 21'st Apr 2022
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will repo
Codexis: A Company Rooting Itself In A Blossoming Market
11:29am, Monday, 18'th Apr 2022
Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals gr
Codexis to Participate in the Cowen 42nd Annual Health Care Conference
09:05pm, Tuesday, 01'st Mar 2022 GlobeNewswire
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42 nd Annual Health Care Conference, being held virtually March 7-9, 2022.
Codexis, Inc. 2021 Q4 - Results - Earnings Call Presentation
04:02pm, Friday, 25'th Feb 2022 Seeking Alpha
Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript
04:41am, Friday, 25'th Feb 2022 Seeking AlphaCodexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript
11:41pm, Thursday, 24'th Feb 2022
Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript
Codexis GAAP EPS of -$0.16 beats by $0.04, revenue of $24.5M beats by $1.35M
09:25pm, Thursday, 24'th Feb 2022 Seeking Alpha
Codexis press release (CDXS): Q4 GAAP EPS of -$0.16 beats by $0.04.Revenue of $24.5M (+16.7% Y/Y) beats by $1.35M.Outlook: Company Guides to 2022 Total Revenues of…
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
08:00pm, Thursday, 24'th Feb 2022
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
